乐球直播

乐球直播

Eplontersen may preserve health status in transthyretin amyloidosis with cardiomyopathy - 乐球体育

2026-10-27
By: 乐球直播
Share:
乐球直播携手体育科技公司,共创赛事新体验! - 乐球直播
乐球直播携手体育科技公司,共创赛事新体验! - 乐球直播
乐球直播携手体育科技公司,共创赛事新体验! - 乐球直播

PHOENIX — Eplontersen monotherapy without baseline transthyretin stabilizers preserved the health status of patients with transthyretin amyloidosis with cardiomyopathy out to 140 weeks, a speaker reported.The results of a post hoc analysis of the CARDIO-TTRansform trial of eplontersen (Wainua, Ionis...

Watch Now

HD Lag-Free Live Broadcast
Your Nickname:
Your Phone:
Watch Now
乐球直播
乐球直播
乐球直播 Technology Co., Ltd.Dedicated to providing the smoothest, clearest, and most comprehensive event live broadcast and information services for global sports enthusiasts.Phone:+86 139 2501 2469Email:[email protected]WeChat:leqiu_158Block 395, North District, Science and Technology Park, Nanshan District, Shenzhen